Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 6:4:38.
doi: 10.1038/s41541-019-0133-5. eCollection 2019.

Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination

Affiliations

Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination

Victoria Bradt et al. NPJ Vaccines. .

Abstract

Flaviviruses have an increasing global impact as arthropod-transmitted human pathogens, exemplified by Zika, dengue, yellow fever (YF), West Nile, Japanese encephalitis, and tick-borne encephalitis (TBE) viruses. Since all flaviviruses are antigenically related, they are prone to phenomena of immunological memory ('original antigenic sin'), which can modulate immune responses in the course of sequential infections and/or vaccinations. In our study, we analyzed the influence of pre-existing YF vaccine-derived immunity on the antibody response to TBE vaccination. By comparing samples from YF pre-vaccinated and flavivirus-naive individuals, we show that YF immunity not only caused a significant impairment of the neutralizing antibody response to TBE vaccination but also a reduction of the specific TBE virus neutralizing activities (NT/ELISA-titer ratios). Our results point to a possible negative effect of pre-existing cross-reactive immunity on the outcome of flavivirus vaccination that may also pertain to other combinations of sequential flavivirus infections and/or vaccinations.

Keywords: Viral infection; Virology.

PubMed Disclaimer

Conflict of interest statement

Competing interestsV.B., S.M., A.v.B., J.J., G.T., I.M., K.W., K.S. and F.X.H. declare no competing interests. U.K. declares to have the following competing interest: He has received travel grants and an unrestricted educational grants from Baxter Healthcare Inc. (Austria), which was the manufacturer of the TBE-vaccine used. He also declares that Baxter and its representatives had no influence on the planning, protocol and conduction of the study nor on the analysis and interpretation of the data.

Figures

Fig. 1
Fig. 1
Structure of TBE virus E protein and TBE vaccination schedule. a Ribbon diagram of the TBE virus E dimer (PDB: 5O6A;) in side view and b surface representation of TBE virus E dimer (PDB: 1SVB;) in top view (lacking the stem and transmembrane domains (TMD)). Color code: DI, red; DII, yellow; DIII, blue; stem, green; TMD, gray; the fusion loop (FL) is highlighted in orange. c Time schedule of TBE vaccination (top – blue arrows) and blood withdrawals (bottom – red arrows). The structures were generated with PyMol (Schrödinger, LLC; www.pymol.org) using published PDB files (https://www.rcsb.org)
Fig. 2
Fig. 2
ELISA and neutralization tests of TBE post-vaccination plasma pools. Blue lines and filled symbols (mean values): Plasma pools of flavivirus-naive group. Red lines and filled symbols (mean values): Plasma pools of YF pre-vaccinated group. Open circles show results of independent experiments. Testing was performed in TBE and YF ELISA (a, c), as well as TBE and YF NT (b, d) at five different time points in the course of TBE vaccination (Fig. 1c). Arrows indicate time points of vaccination. Error bars represent the standard errors of the means (SEM) calculated from at least three independent experiments. Asterisks indicate significant differences between the two groups at the different time points (measured by t-test): **P < 0.01; ***P < 0.001; ****P < 0.0001
Fig. 3
Fig. 3
Den and RB ELISA of TBE post-vaccination plasma pools. Blue lines and filled symbols (mean values): Plasma pools of flavivirus-naive group. Red lines and filled symbols (mean values): Plasma pools of YF pre-vaccinated group. Open circles show results of independent experiments. Testing was performed in a Den and b RB ELISA at five different time points in the course of TBE vaccination (Fig. 1c). Arrows indicate time points of vaccination. Error bars represent the SEM calculated from at least three independent experiments. Asterisks indicate significant differences between the two groups at the different time points (measured by t-test): **P < 0.01; ***P < 0.001
Fig. 4
Fig. 4
ELISA of TBE post-vaccination plasma pools at time point 28 weeks before (control) and after depletion of cross-reactive antibodies with RB sE. Blue columns (mean values): Plasma pool of flavivirus-naive group. Red columns (mean values): Plasma pool of YF pre-vaccinated group. Open circles show results of independent experiments. a RB ELISA. b Den ELISA. c TBE ELISA. d YF ELISA. Error bars represent the SEM calculated from three independent experiments
Fig. 5
Fig. 5
NTs of TBE post-vaccination plasma pools at time point 28 weeks before (control) and after depletion of cross-reactive antibodies with RB sE. Blue columns (mean values): Plasma pool of flavivirus-naive group. Red columns (mean values): Plasma pool of YF pre-vaccinated group. Open circles show results of independent experiments. a TBE NT. b YF NT. Error bars represent the SEM calculated from at least three independent experiments. No statistically significant difference was observed before and after depletion (measured by t-test)
Fig. 6
Fig. 6
TBE ELISA and NT of individual TBE post-vaccination plasma samples at time point 28 weeks. Blue circles: Plasma samples from flavivirus-naive individuals. Red squares: Plasma samples form YF pre-vaccinated individuals. The values of the symbols represent the means of three to four independent experiments. Solid lines: Means of individual values. Dotted lines: Results of plasma pools. a TBE ELISA. b Fold differences of individual ELISA values to the means of all ELISA titers. c TBE NT. d Fold differences of individual NT titers to the means of all NT titers. Asterisks in a and c indicate significant differences between the two groups (measured by t-test): *P < 0.05; ****P < 0.0001
Fig. 7
Fig. 7
Fold differences of TBE ELISA a and TBE NT b to RB ELISA titers of individual TBE post-vaccination sera at time point 28 weeks. Blue circles: Plasma samples from flavivirus-naive individuals. Red squares: Plasma samples form YF pre-vaccinated individuals. The values of the symbols represent the means of three independent experiments. Ratios of TBE ELISA and NT titers to RB titers were calculated and expressed as the fold difference to the respective mean of the two groups
Fig. 8
Fig. 8
Correlation of ELISA and NT of TBE post-vaccination plasma samples at time point 28 weeks. Blue lines and circles: Plasma samples from flavivirus-naive individuals. Red lines and squares: Plasma samples from YF pre-vaccinated individuals. The values of the symbols represent the means of three to four independent experiments. a Linear regression of TBE ELISA and TBE NT50 titers. Spearman correlation coefficients (r) are indicated for both groups. b Ratios of TBE NT50 titers and TBE ELISA titers of individual plasma samples of both groups. Solid line: means of all single sera. Asterisks in b indicate significant differences between the two groups (measured by t-test): ***P < 0.001

Similar articles

Cited by

References

    1. Wilder-Smith A, et al. Epidemic arboviral diseases: priorities for research and public health. Lancet Infect. Dis. 2017;17:e101–e106. doi: 10.1016/S1473-3099(16)30518-7. - DOI - PubMed
    1. Petersen LR, Brault AC, Nasci RS. West Nile virus: review of the literature. JAMA. 2013;310:308–315. doi: 10.1001/jama.2013.8042. - DOI - PMC - PubMed
    1. Weaver SC, et al. Zika virus: History, emergence, biology, and prospects for control. Antivir. Res. 2016;130:69–80. doi: 10.1016/j.antiviral.2016.03.010. - DOI - PMC - PubMed
    1. Bhatt Samir, Gething Peter W., Brady Oliver J., Messina Jane P., Farlow Andrew W., Moyes Catherine L., Drake John M., Brownstein John S., Hoen Anne G., Sankoh Osman, Myers Monica F., George Dylan B., Jaenisch Thomas, Wint G. R. William, Simmons Cameron P., Scott Thomas W., Farrar Jeremy J., Hay Simon I. The global distribution and burden of dengue. Nature. 2013;496(7446):504–507. doi: 10.1038/nature12060. - DOI - PMC - PubMed
    1. Heinz, F. X. & Stiasny, K. The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. Microbiol. Mol. Biol. Rev.81, 10.1128/MMBR.00055-16 (2017). - PMC - PubMed